Last updated: August 06, 2026

Application No. 18/485,224

INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF

Non-Final OA

Filed

Oct 11, 2023

Priority

Oct 12, 2022 — provisional 63/415,590 +2 more

Examiner

ROMERO, KRISTEN WANG

Art Unit

1624

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Maze Therapeutics Inc.

OA Round

2 (Non-Final)

Interview Optional

— +29.8% interview lift. Examiner has a relatively high allowance rate (71%); +29.8% interview lift. A written response may suffice.

Based on 38 resolved cases, 2023–2026

Examiner Intelligence

ROMERO, KRISTEN WANG View full profile →

Grants 71% — above average

Career Allowance Rate

27 granted / 38 resolved

+11.1% vs TC avg

Strong +30% interview lift

Without

With

+29.8%

Interview Lift

resolved cases with interview

Typical timeline

3y 2m

Avg Prosecution

33 currently pending

Career history

Total Applications

across all art units

Statute-Specific Performance

§101

4.5%

-35.5% vs TC avg

§103

20.0%

-20.0% vs TC avg

§102

21.1%

-18.9% vs TC avg

§112

38.1%

-1.9% vs TC avg

Black line = Tech Center average estimate • Based on career data from 38 resolved cases

Prosecution Timeline

Oct 11, 2023

Application Filed

Mar 12, 2026

Non-Final Rejection mailed

Jun 12, 2026

Response Filed

Jul 28, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/035,694

Patent 12691093

METHODS TO SENSITIZE CANCER CELLS TO IMMUNE ATTACK USING ATRACTYLENOLIDE I

3y 2m to grant Granted Jul 28, 2026

18/018,805

Patent 12673052

COMBINATIONS FOR THE TREATMENT OF CANCER

3y 5m to grant Granted Jul 07, 2026

18/267,691

Patent 12653802

METHOD FOR TREATING LUNG CANCER

3y 0m to grant Granted Jun 16, 2026

17/627,590

Patent 12649732

POLYMORPHS OF (R)-N-(5-(5-ISOPROPYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-2-METHYL-2H-TETRAZOLE-5-CARBOXAMIDE

4y 4m to grant Granted Jun 09, 2026

18/087,881

Patent 12630505

Alkyne Compound, Vitamin D Compound, Analytical Method, and Production Method

3y 4m to grant Granted May 19, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3

Expected OA Rounds

71%

Grant Probability

99%

With Interview (+29.8%)

3y 2m (~4m remaining)

Median Time to Grant

Moderate

PTA Risk

Based on 38 resolved cases by this examiner. Grant probability derived from career allowance rate.